Procedure
Peanut protein
Peanut protein is a medical procedure with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
PROCEDURE
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
33%(1 trials)
Phase Distribution
Ph early_phase_1
1
25%
Ph not_applicable
1
25%
Ph phase_2
2
50%
Phase Distribution
1
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Early Phase 1First-in-human
1(25.0%)
Phase 2Efficacy & side effects
2(50.0%)
N/ANon-phased studies
1(25.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Completed(3)
Detailed Status
Completed3
Enrolling by invitation1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Early Phase 11 (25.0%)
Phase 22 (50.0%)
N/A1 (25.0%)
Trials by Status
completed375%
enrolling_by_invitation125%
Recent Activity
0 active trials
Showing 4 of 4
enrolling_by_invitationnot_applicable
Peanut Sip Feeding Protocol
NCT06693544
completedphase_2
Immune Basis and Clinical Implications of Threshold-based Phenotypes of Peanut Allergy
NCT03907397
completedphase_2
Peanut Allergy Oral Immunotherapy Desensitization
NCT01601522
completedearly_phase_1
Oral Peanut Immunotherapy for Peanut Allergic Patients
NCT01891136
Clinical Trials (4)
Showing 4 of 4 trials
NCT06693544Not Applicable
Peanut Sip Feeding Protocol
NCT03907397Phase 2
Immune Basis and Clinical Implications of Threshold-based Phenotypes of Peanut Allergy
NCT01601522Phase 2
Peanut Allergy Oral Immunotherapy Desensitization
NCT01891136Early Phase 1
Oral Peanut Immunotherapy for Peanut Allergic Patients
All 4 trials loaded
Drug Details
- Intervention Type
- PROCEDURE
- Total Trials
- 4